Nina Raulf

1.0k total citations · 1 hit paper
13 papers, 696 citations indexed

About

Nina Raulf is a scholar working on Molecular Biology, Cancer Research and Oncology. According to data from OpenAlex, Nina Raulf has authored 13 papers receiving a total of 696 indexed citations (citations by other indexed papers that have themselves been cited), including 12 papers in Molecular Biology, 7 papers in Cancer Research and 5 papers in Oncology. Recurrent topics in Nina Raulf's work include Cell death mechanisms and regulation (4 papers), RNA Interference and Gene Delivery (4 papers) and MicroRNA in disease regulation (4 papers). Nina Raulf is often cited by papers focused on Cell death mechanisms and regulation (4 papers), RNA Interference and Gene Delivery (4 papers) and MicroRNA in disease regulation (4 papers). Nina Raulf collaborates with scholars based in United Kingdom, Germany and Singapore. Nina Raulf's co-authors include Mahvash Tavassoli, Philippe Lucarelli, Thomas Sauter, Elham Alsahafi, Katheryn Begg, Ivano Amelio, Nagy Habib, Albert Kwok, Joop Gäken and Edward Odell and has published in prestigious journals such as Nucleic Acids Research, Journal of Biological Chemistry and Journal of Clinical Oncology.

In The Last Decade

Nina Raulf

13 papers receiving 691 citations

Hit Papers

align trajectories

What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

Clinical update on head and neck cancer: molecular biology and ongoing challenges

2019 369 citations Elham Alsahafi, Katheryn Begg et al. Cell Death and Disease profile →

Peers

Countries citing papers authored by Nina Raulf

Since Specialization

Citations

This map shows the geographic impact of Nina Raulf's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Nina Raulf with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Nina Raulf more than expected).

Fields of papers citing papers by Nina Raulf

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Nina Raulf. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Nina Raulf. The network helps show where Nina Raulf may publish in the future.

Co-authorship network of co-authors of Nina Raulf

This figure shows the co-authorship network connecting the top 25 collaborators of Nina Raulf. A scholar is included among the top collaborators of Nina Raulf based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Nina Raulf. Nina Raulf is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

13 of 13 papers shown

#	Work	Indexed citations
1	515 A phase 1 study of myeloid modulating agent MTL-CEBPA in combination with pembrolizumab in adult patients with advanced solid tumours 2021 ·SHILAP Revista de lepidopterología ·Ruth Plummer, Mikael H. Sodergren, David J. Pinato, Debashis Sarker, Vikash Reebye, Duncan Spalding, Nina Raulf, (unknown), Thomas Talbot, Alessio Cortellini, Antonio D’Alessio, Ilian Tchakov, Robert Habib, John J. Rossi, (unknown)	1
2	Phase Ib dose escalation and cohort expansion study of the novel myeloid differentiating agent MTL-CEBPA in combination with sorafenib in patients with advanced hepatocellular carcinoma (HCC). 2020 ·Journal of Clinical Oncology ·Debashis Sarker, Mikael H. Sodergren, Elizabeth Ruth Plummer, Bristi Basu, Tim Meyer, Kai‐Wen Huang, T.R. Jeffry Evans, Duncan Spalding, Yuk Ting, Daniel H. Palmer, Cheng Ean Chee, David J. Pinato, Vikash Reebye, (unknown), Nina Raulf, (unknown), Pinelopi Andrikakou, Robert Habib, David C. Blakey, Nagy Habib	1
3	First-in-human phase I trial of small activating RNA (saRNA) oligonucleotide MTL-CEBPA in combination with sorafenib in patients with advanced hepatocellular carcinoma (HCC). 2020 ·Journal of Clinical Oncology ·Debashis Sarker, Mikael H. Sodergren, Elizabeth Ruth Plummer, Bristi Basu, Tim Meyer, Kai‐Wen Huang, T.R. Jeffry Evans, Duncan Spalding, Yuk Ting, Daniel H. Palmer, Cheng Ean Chee, David J. Pinato, Vikash Reebye, (unknown), Nina Raulf, (unknown), Pinelopi Andrikakou, Robert Habib, David C. Blakey, Nagy Habib	3
4	Clinical update on head and neck cancer: molecular biology and ongoing challenges breakdown → 2019 ·Cell Death and Disease ·Elham Alsahafi, Katheryn Begg, Ivano Amelio, Nina Raulf, Philippe Lucarelli, Thomas Sauter, Mahvash Tavassoli	369
5	Developing Small Activating RNA As a Therapeutic: Current Challenges and Promises 2019 ·Therapeutic Delivery ·Albert Kwok, Nina Raulf, Nagy Habib	61
6	Annexin A1 regulates EGFR activity and alters EGFR-containing tumour-derived exosomes in head and neck cancers 2018 ·European Journal of Cancer ·Nina Raulf, Philippe Lucarelli, Selvam Thavaraj, Stacey-Ann Whittaker Brown, José M. Vicencio, Thomas Sauter, Mahvash Tavassoli	54
7	MicroRNA‐9 inhibits growth and invasion of head and neck cancer cells and is a predictive biomarker of response to plerixafor, an inhibitor of its target CXCR4 2018 ·Molecular Oncology ·(unknown), Nina Raulf, Joop Gäken, (unknown), Mahvash Tavassoli	32
8	Differential response of head and neck cancer cell lines to TRAIL or Smac mimetics is associated with the cellular levels and activity of caspase-8 and caspase-10 2014 ·British Journal of Cancer ·Nina Raulf, (unknown), Dagmar Kulms, Daniele Lecis, D Delia, Henning Walczak, (unknown), Edward Odell, Mahvash Tavassoli	22
9	Bortezomib sensitises TRAIL-resistant HPV-positive head and neck cancer cells to TRAIL through a caspase-dependent, E6-independent mechanism 2014 ·Cell Death and Disease ·(unknown), Nina Raulf, (unknown), Henning Walczak, Dagmar Kulms, Edward Odell, Selvam Thavaraj, Manoochehr Tavassoli	21
10	MicroRNA‐196a promotes an oncogenic effect in head and neck cancer cells by suppressing annexin A1 and enhancing radioresistance 2014 ·International Journal of Cancer ·Yae‐Eun Suh, Nina Raulf, Joop Gäken, Katherine Lawler, Teresa Guerrero Urbano, (unknown), Stéphane Gobeil, Jacques Huot, Edward Odell, Mahvash Tavassoli	85
11	Cytosolic Bax 2012 ·Journal of Biological Chemistry ·Sandra Vogel, Nina Raulf, Stephanie Bregenhorn, Martin L. Biniossek, Ulrich Maurer, Peter E. Czabotar, Christoph Borner	28
12	NIR, an inhibitor of histone acetyltransferases, regulates transcription factor TAp63 and is controlled by the cell cycle 2010 ·Nucleic Acids Research ·Kristina Heyne, Vivienne Willnecker, Jochen G. Schneider, Marcel E. Conrad, Nina Raulf, Roland Schüle, Klaus Roemer	17
13	Mechanisms of Bax/Bak activation: Is there any light at the end of the tunnel? 2009 ·(unknown), Thomas Kiefer, Nina Raulf, (unknown), Anand Manoharan, Christoph Borner	2

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact